Radiation Therapy as an Immunomodulator

Size: px
Start display at page:

Download "Radiation Therapy as an Immunomodulator"

Transcription

1 Radiation Therapy as an Immunomodulator Yvonne Mowery, MD, PhD February 20, 2017 Tumor/Immune System Balance Kalbasi, JCI 2013

2 UNC-Duke-NC State-Wake Forest Spring RT Can Shift Balance Toward Elimination Kalbasi, JCI 2013 Radiation-Induced Immune Stimulation Exposure of new tumor antigens MHC-I expression chemokines à recruit cytotoxic T-cells TCR repertoire diversity death receptors à cytotoxic T-cell activity Abscopal effect Sharabi, Lancet Onc 2015

3 UNC-Duke-NC State-Wake Forest Spring Overview of Antitumor Immune Response Makkouk, Canc Res 2015 Immune Synapse Peptide-MHC T cell receptor Antiinflammatory Proinflammatory Grass, Curr Prob Canc 2016

4 Tumor-Immune Cell Interaction Ma, J Heme Onc 2016 CTLA-4 and PD-1 Immune Checkpoints Topalian, Nature Reviews 2016

5 RT Synergy with CTLA-4 and PD-1 Checkpoint Blockade in vivo RT = 20 Gy x 1 C4 = anti-ctla-4 Ab P1 = anti-pd-l1 Ab Proportion survival Proportion survival Days Syngeneic melanoma cell line (B16-F10) Twyman Saint-Victor, Nature 2016 CD8+ T-cells and Tregs with RT + Immune Checkpoint Blockade Treg CD8 Twyman Saint-Victor, Nature 2016

6 CD8+ T-cells Reinvigorated after RT and Immune Checkpoint Blockade Reinvigorated = GzmB + Ki67 + Exhausted = GzmB - Ki67 - Twyman Saint-Victor, Nature 2016 RT Increases T Cell Receptor Diversity Tumor Infiltrating Lymphocytes Broader TCR repertoire associated with clinical benefit to anti-ctla-4 TCR Twyman Saint-Victor, Nature 2016 Postow, J Immuno Cancer 2015

7 Optimal RT Timing Varies for Different Immunomodulatory Targets Young, PLOS One 2016 RT and Ipilimumab Timing in Metastatic Melanoma Ipi before RT Ipi after RT Qin, IJROBP 2016

8 Potential Impact of RT Fractionation on Immunologic Effect 9H10 = anti-ctla-4 Ab Primary Tumor Secondary Tumor TSA cell line (murine poorly immunogenic mammary carcinoma) Abscopal effect with fractionated RT only (8 Gy x 3 or 6 Gy x 5) No Abscopal effect with 20 Gy x 1 Dewan, Clin Canc Res 2009 Tumor-Specific Memory Response with RT + anti- CD40 agonist Murine lymphoma model (10 Gy) Tumor rechallenge for surviving mice from above (> 60 days after initial tumor) Dovedi, Cancer Imm Res 2016

9 Dendritic Cells and CD8+ T cells Required for Tumor Control by RT + anti-cd40 agonist Dendritic Cell Depletion (DT) abrogates response to RT + anti-cd40 CD8 T-cell depletion abrogates response to RT + anti-cd40 Dovedi, Cancer Imm Res 2016 RT Modifies the Tumor Microenvironment DAMP = dangerassociated molecular pattern Deloch, Frontiers Onc 2016

10 RT-Induced Immunogenic Cell Death Immunogenic cell death DAMP release/cell surface expression Calreticulin (CRT) ATP High-mobility group box 1 (HMGB1) Type I IFN Maturation of APCs Promotes Phagocytic Uptake Activation of Effector Immune Cells Cytoxic T Cell-Mediated Tumor Cell Lysis Grass, CurrProb Canc2016 RT-Induced Calreticulin à Increased Sensitivity to Cytotoxic T Lymphocyte (CTL) Lysis Non-Cancer Stem Cells Cancer Stem Cells CTL Lysis Assay CBP = Calreticulin Binding Protein LCMV = lymphocytic choriomeningitis virus peptide (negative control) Gameiro, IJROBP 2016

11 Radiation Induces T Cell Priming Without RT à Tolerance RT à Cross-Presentation à Immunity Spiotto, Sci. Imm RT Activates Pro-Inflammatory Pathways Spiotto, Sci Imm 2016

12 RT Increases IFNb Production by Immune & Tumor Cells Tumor response to RT abrogated by IFN receptor knock-out Burnette, Canc Res 2011 RT Increases T cell Infiltration & Effector Response Spiotto et al, Sci Imm 2016

13 RT Effects on Tumor Microenvironment Promoting T cell Recruitment Vascular normalization secretion of chemokines à recruit CD8+ T cells Upregulation of MHC-I, Fas, ICAM-, natural-killer group 2 member D (NKG2D-L) on tumor cells à improved tumor cell killing Negative effect: PD-L1 on tumor cells Demaria, JAMA Onc 2015 Increased CD8+ T cells after RT and Synergy with anti-pd-1 Ab Sharabi, Cancer Imm Res 2015

14 Increased Immune Cell Infiltrate after RT Hematopoietic Cells Dendritic Cells Myeloid cell marker Dendritic Cell marker B16F1 tumors or tumors treated with 25 Gy local RT Burnette, Canc Res 2011 Tumor-Infiltrating Dendritic Cells (TIDC) from Irradiated Tumor Stimulate T Cell Proliferation T cell Proliferation Effect abrogated in IFN receptor knockout mice (KO) SIY = exogenous tumorassociated antigen Burnette, Canc Res 2011

15 UNC-Duke-NC State-Wake Forest Spring RT-Induced Abscopal Response Whiteside, Clin Canc Res 2016 Abscopal Response after RT + Ipilimumab SBRT (2-3 fractions) à 3-5 days à ipilimumab Twyman-Saint Victor, Nature 2015

16 UNC-Duke-NC State-Wake Forest Spring Abscopal Response after RT + Ipilimumab RT dose < 3 Gy associated with better response (81% vs. 52% favorable, p = 0.014) Chandra, Oncoimmunology 2015 Out-of-Field DNA Damage after RT g-h2ax foci in hair follicles outside of RT field Corresponding changes in plasma levels of certain cytokines: MDC/CCL22: secreted by macrophages and dendritic cells MIP-1a/CCL3: attract macrophages, monocytes, neutrophils Siva, Clin Can Res 2016

17 RT-Induced Complement Activation Involved in Tumor Control Green = C3 cleavage products Regal, Ann Tran Med 2016 Summary of Immune-Related Anti-Tumor Effects of RT Bernstein, Nature Reviews 2016

18 RT and Immunotherapy in T cell Negative Tumors Demaria, JAMA Onc 2015 RT and Immunotherapy in T cell Poor Tumors Demaria, JAMA Onc 2015

19 UNC-Duke-NC State-Wake Forest Spring Ongoing studies investigating RT combined with tumor vaccines, CAR T cells, immune checkpoint blockade, immune costimulatory agonists Whiteside, Clin Canc Res 2016 RT Induces Pro- & Anti-Immune Signals Immunosuppressive aspects of RT can counterbalance immunemediated tumor control Demaria, JAMA Onc 2015

20 UNC-Duke-NC State-Wake Forest Spring RT Fractionation: Pro-Inflammatory Effects Deloch, Frontiers Onc 2016 RT Fractionation: Anti-Inflammatory Effects RT-induced lymphocyte death Increased Tregs Release of immunosuppressive cytokines Upregulation of immune checkpoint molecules (e.g. PD-L1) Deloch, Frontiers Onc 2016

21 Summary RT à pro-inflammatory tumor microenvironment Immune cell infiltration Immunogenic cell death à DAMPs à APC activation Cross-presentation of tumor antigens Complement pathway activation Reinvigorates exhausted T cells and TCR diversity RT can also have anti-inflammatory effects Importance of dose and timing with combined therapy RT à out-of-field tumor effects (Abscopal effect) Particularly combined with other therapies

Darwinian selection and Newtonian physics wrapped up in systems biology

Darwinian selection and Newtonian physics wrapped up in systems biology Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid

More information

Radiation Therapy and Immunotherapy: New Frontiers

Radiation Therapy and Immunotherapy: New Frontiers Radiation Therapy and Immunotherapy: New Frontiers Nevada Oncology Society Fall Meeting November 16 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland Bellefonte Cancer Center Assistant Clinical

More information

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3

More information

Radiotherapie en immunotherapy

Radiotherapie en immunotherapy Radiotherapie en immunotherapy 1+1=3? 5 D dagen, Ermelo Evert Jan Van Limbergen, MD, PhD Radiation oncologist MAASTRO clinic Disclosure No conflict of interest Overzicht Introductie Historisch perspectief

More information

Combining ADCs with Immuno-Oncology Agents

Combining ADCs with Immuno-Oncology Agents Combining ADCs with Immuno-Oncology Agents Chad May, PhD Senior Director Targeted Immunotherapy Oncology Research Unit, Pfizer 7 th Annual World ADC October 10, 2016 Cancer-Immunity Cycle Innate Immunity

More information

Radiation Therapy and Immunotherapy: New Frontiers

Radiation Therapy and Immunotherapy: New Frontiers Radiation Therapy and Immunotherapy: New Frontiers May 12 th, 2017 Anshu K. Jain, MD Radiation Oncologist, Ashland-Bellefonte and Logan Regional Cancer Centers Assistant Professor of Therapeutic Radiology,

More information

Induction of immune response by combining TLR activation and radiotherapy

Induction of immune response by combining TLR activation and radiotherapy Induction of immune response by combining TLR activation and radiotherapy Peter Huber Molecular & Radiation Oncology dkfz/university hospital Heidelberg Nothing to disclose Physical Dose Precision Meningioma

More information

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent

More information

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical

More information

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)

Tumors arise from accumulated genetic mutations. Tumor Immunology (Cancer) Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of

More information

Tim-3 as a target for tumor immunotherapy

Tim-3 as a target for tumor immunotherapy Tim-3 as a target for tumor immunotherapy Ana Carrizosa Anderson Brigham and Women s Hospital Harvard Medical School Disclosures A portion of the work has been performed as part of a sponsored research

More information

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)

5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop

More information

Cancer immunotherapy with oncolytic viruses: more than just lysis

Cancer immunotherapy with oncolytic viruses: more than just lysis Cancer immunotherapy with oncolytic viruses: more than just lysis Dmitriy Zamarin MD PhD Assistant Attending, Immune Therapeutics Center Memorial Sloan-Kettering Cancer Center New York, NY BCAN Think Tank

More information

8/3/2016. Why are abscopal effects of radiation so rare? Radiation therapy to ignite an anti-cancer immune response DISCLOSURES

8/3/2016. Why are abscopal effects of radiation so rare? Radiation therapy to ignite an anti-cancer immune response DISCLOSURES 8/3/216 Radiation therapy to ignite an anti-cancer immune response Silvia Formenti, M.D. Weill Cornell Medical College New York Presbyterian Hospital New York, NY DISCLOSURES Consultant/Speaker: Bristol

More information

The Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils

The Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy

More information

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes

More information

Licia Rivoltini, MD Unit of Immunotherapy of Human Tumors

Licia Rivoltini, MD Unit of Immunotherapy of Human Tumors Licia Rivoltini, MD Unit of Immunotherapy of Human Tumors The complex network of anti-tumor immunity Innate immunity First line defense Tumor cell Adaptive immunity Specificity & memory Kidd et al., Nature

More information

Engineered Immune Cells for Cancer Therapy : Current Status and Prospects

Engineered Immune Cells for Cancer Therapy : Current Status and Prospects When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU

More information

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School

Tumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor

More information

M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology

M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology Code : AS-2246 M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology A. Select one correct option for each of the following questions:- 2X10=10 1. (b)

More information

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant

Tumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be

More information

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS 1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Table S1: Combination Immunotherapy: Small Molecules that Boost Immune Response in Combination with Other Agents Target Compound (MOA) NLG919 and indoximod 1- MT Combination Model Observation Reference

More information

The Immune System. A macrophage. ! Functions of the Immune System. ! Types of Immune Responses. ! Organization of the Immune System

The Immune System. A macrophage. ! Functions of the Immune System. ! Types of Immune Responses. ! Organization of the Immune System The Immune System! Functions of the Immune System! Types of Immune Responses! Organization of the Immune System! Innate Defense Mechanisms! Acquired Defense Mechanisms! Applied Immunology A macrophage

More information

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates

Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical

More information

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16

COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand

More information

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard

More information

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline 1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for

More information

Immunotherapie: algemene principes

Immunotherapie: algemene principes Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):

More information

Immunology and Immunotherapy 101 for the Non-Immunologist

Immunology and Immunotherapy 101 for the Non-Immunologist Immunology and Immunotherapy 101 for the Non-Immunologist Stephen P. Schoenberger, Ph.D La Jolla Institute for Allergy and Immunology & UCSD Moores Cancer Center Disclosures Human Longevity Inc: Salary

More information

Discover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15

Discover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15 Discover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15 Immunology in cancer The role of immunology in cancer Evolving knowledge of the immune system has provided a better understanding of

More information

Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use

Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org

More information

Professor Mark Bower Chelsea and Westminster Hospital, London

Professor Mark Bower Chelsea and Westminster Hospital, London Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing

More information

NKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology

NKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017

More information

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses

More information

Convergence of radiation and immunogenic signaling pathways

Convergence of radiation and immunogenic signaling pathways Convergence of radiation and immunogenic signaling pathways Silvia Formenti, M.D. Weill Cornell Medical College New York Presbyterian Hospital New York, NY Principal Investigator: DISCLOSURES Consultant/Speaker:

More information

1. Overview of Adaptive Immunity

1. Overview of Adaptive Immunity Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive

More information

Interleukin-2 Single Agent and Combinations

Interleukin-2 Single Agent and Combinations Interleukin-2 Single Agent and Combinations Michael K Wong MD PhD Norris Cancer Center University of Southern California mike.wong@med.usc.edu Disclosures Advisory Board Attendance Merck Bristol Myers

More information

NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity

NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity Peiwen Kuo Scientist, Research Biology Nektar Therapeutics August 31 st, 2018 Emerging

More information

Synergistic combinations of targeted immunotherapy to combat cancer

Synergistic combinations of targeted immunotherapy to combat cancer Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic

More information

Tumor Microenvironment and Immune Suppression

Tumor Microenvironment and Immune Suppression Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation

More information

PD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs

PD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs PD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs Steven Dow, DVM, PhD Department of Clinical Sciences, Animal Cancer Center Colorado State University Consortium

More information

WIN 2015 Symposium Radiation and immunology: a new therapeutic partnership

WIN 2015 Symposium Radiation and immunology: a new therapeutic partnership WIN 215 Symposium Radiation and immunology: a new therapeutic partnership Dr. Ralph Weichselbaum Conflict of Interest Nothing to Disclose Limitations of Radiotherapy Radiotherapy cannot be given in high

More information

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?

More information

Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.

Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,

More information

TCR, MHC and coreceptors

TCR, MHC and coreceptors Cooperation In Immune Responses Antigen processing how peptides get into MHC Antigen processing involves the intracellular proteolytic generation of MHC binding proteins Protein antigens may be processed

More information

June IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)

June IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our

More information

Adaptive immune responses: T cell-mediated immunity

Adaptive immune responses: T cell-mediated immunity MICR2209 Adaptive immune responses: T cell-mediated immunity Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will discuss the T-cell mediated immune response, how it is activated,

More information

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015

Checkpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015 Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib

More information

Adaptive (acquired) immunity. Professor Peter Delves University College London

Adaptive (acquired) immunity. Professor Peter Delves University College London Adaptive (acquired) immunity Professor Peter Delves University College London p.delves@ucl.ac.uk Haematopoiesis Haematopoiesis Lymphocytes = adaptive response Recognition of pathogens by adaptive cells,

More information

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:

More information

Immunotherapy of Prostate Cancer

Immunotherapy of Prostate Cancer Immunotherapy of Prostate Cancer Robert E. Reiter MD MBA Bing Professor of Urologic Oncology Geffen School of Medicine at UCLA Costimulatory expression required for T cell activation Therapeutic Vaccines

More information

Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies

Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite

More information

DISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding

DISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this

More information

Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD

Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.

More information

Nivolumab in Hodgkin Lymphoma

Nivolumab in Hodgkin Lymphoma Nivolumab in Hodgkin Lymphoma Stephen M. Ansell, MD, PhD Professor of Medicine Chair, Lymphoma Group Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers Squibb Celldex Therapeutics Seattle

More information

Atelier anti-pd1 Recherche de cible

Atelier anti-pd1 Recherche de cible Atelier anti-pd1 Recherche de cible Nathalie Bonnefoy Institut de Recherche en Cancérologie de Montpellier Equipe Immunité et Cancer Nathalie.bonnefoy@inserm.fr Majid Khatib Laboratoire de l'angiogénèse

More information

Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.

Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D. Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research

More information

Immunotherapy: The Newest Treatment Route

Immunotherapy: The Newest Treatment Route Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William

More information

A Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma

A Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma A Prospective Phase II Trial of Deintensified Chemoradiation Therapy for Low Risk HPV Associated Oropharyngeal Squamous Cell Carcinoma B. S. Chera 1, R. J. Amdur 2, J. E. Tepper 3, B. Qaqish 4, R. Green

More information

Co-operative Radio-Immune-Stimulating Cancer Therapy by Bertil R.R. Persson PhD, MDh.c Professor emeritus of medical radiation physics at Lund

Co-operative Radio-Immune-Stimulating Cancer Therapy by Bertil R.R. Persson PhD, MDh.c Professor emeritus of medical radiation physics at Lund Co-operative Radio-Immune-Stimulating Cancer Therapy by Bertil R.R. Persson PhD, MDh.c Professor emeritus of medical radiation physics at Lund University, 221 85 LUND Sweden. E-mail: bertil_r.persson@med.lu.se

More information

Immunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia

Immunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia Immunity and Cancer Doriana Fruci Lab di Immuno-Oncologia Immune System is a network of cells, tissues and organs that work together to defend the body against attacks of foreign invaders (pathogens, cancer

More information

Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy

Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Combination Immunotherapy Approaches Chemotherapy, Radiation Therapy, and Dual Checkpoint Therapy Dr. David B. Page Providence Portland Medical Center Earle A. Chiles Research Institute Funding & Disclosures

More information

Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach

Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response

More information

Immunotherapy and Radiation

Immunotherapy and Radiation Immunotherapy and Radiation Jonathan Schoenfeld MD MPH Melanoma Radiation Oncology Director, Center for Head and Neck Oncology, Center for Immune Oncology Department of Radiation Oncology Assistant Professor,

More information

IMMU 7630 Fall 2018 TUMOR IMMUNOLOGY

IMMU 7630 Fall 2018 TUMOR IMMUNOLOGY TUMOR IMMUNOLOGY CANCER. About 610,000 people in the United States will die of cancer in 2018 1. It is the second leading cause of death, after heart disease. After accidents, it is the second leading

More information

Cancer Immunotherapy: Active Immunization Approaches

Cancer Immunotherapy: Active Immunization Approaches Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships

More information

Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade

Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING

More information

Oligometastases: Radiotherapy

Oligometastases: Radiotherapy Oligometastases: Radiotherapy Prof. Dirk De Ruysscher, MD, PhD Radiation Oncologist Maastro clinic, Maastricht University Medical Center/ GROW Maastricht The Netherlands Disclosure Advisory board of Bristol-Myers

More information

Attribution: University of Michigan Medical School, Department of Microbiology and Immunology

Attribution: University of Michigan Medical School, Department of Microbiology and Immunology Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution

More information

Cellular Immune response. Jianzhong Chen, Ph.D Institute of immunology, ZJU

Cellular Immune response. Jianzhong Chen, Ph.D Institute of immunology, ZJU Cellular Immune response Jianzhong Chen, Ph.D Institute of immunology, ZJU Concept of adaptive immune response T cell-mediated adaptive immune response I. Concept of immune response A collective and coordinated

More information

Basic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA

Basic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer

More information

IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia

IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as

More information

International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting

International Society of Breast Pathology. Immune Targeting in Breast Cancer. USCAP 2017 Annual Meeting International Society of Breast Pathology USCAP 2017 Annual Meeting Immune Targeting in Breast Cancer Ashley Cimino-Mathews, MD Assistant Professor of Pathology and Oncology The Johns Hopkins Hospital

More information

Priming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics

Priming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer

More information

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.

More information

Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells

Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells 1 Immunological tolerance and immune regulation Abul K. Abbas UCSF 2 Lecture outline Central and peripheral tolerance Inhibitory receptors of T cells Regulatory T cells 1 The immunological equilibrium:

More information

Nobel Prize in Physiology or Medicine 2018

Nobel Prize in Physiology or Medicine 2018 Nobel Prize in Physiology or Medicine 2018 Arunika Mukhopadhaya The Nobel Prize in Physiology or Medicine for the year 2018 was awarded to James P Allison of the United States and Tasuku Honjo of Japan

More information

Advances in Cancer Immunotherapy

Advances in Cancer Immunotherapy Advances in Cancer Immunotherapy Immunology 101 for the Non-Immunologist Arnold H. Zea, PhD azea@lsuhsc.edu Disclosures No relevant financial relationships to disclose This presentation does not contain

More information

Immunotherapy and Radiation

Immunotherapy and Radiation Immunotherapy and Radiation Jonathan Schoenfeld MD MPH Melanoma Radiation Oncology Director, Center for Head and Neck Oncology, Center for Immune Oncology Department of Radiation Oncology Assistant Professor,

More information

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY

More information

Immunological alterations in mice irradiated with low doses

Immunological alterations in mice irradiated with low doses Immunological alterations in mice irradiated with low doses "Frédéric Joliot-Curie" National Research Institute for Radiobiology and Radiohygiene, Budapest, Hungary The structure of the immune system INNATE

More information

Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy

Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Molecular mechanisms of the T cellinflamed tumor microenvironment: Implications for cancer immunotherapy Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

Tumor Immunology: A Primer

Tumor Immunology: A Primer Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

Emerging Concepts of Cancer Immunotherapy

Emerging Concepts of Cancer Immunotherapy Emerging Concepts of Cancer Immunotherapy Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Immune Cell Infiltrate in Primary

More information

The immune response against cancer

The immune response against cancer The immune response against cancer Maries van den Broek Institute of Experimental Immunology vandenbroek@immunology.uzh.ch The immune system Main cells of the immune system Dendritic cell Monocyte Macrophage

More information

2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery

2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los

More information

Defensive mechanisms include :

Defensive mechanisms include : Acquired Immunity Defensive mechanisms include : 1) Innate immunity (Natural or Non specific) 2) Acquired immunity (Adaptive or Specific) Cell-mediated immunity Humoral immunity Two mechanisms 1) Humoral

More information

Exploring Immunotherapies: Beyond Checkpoint Inhibitors

Exploring Immunotherapies: Beyond Checkpoint Inhibitors Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction

More information

IMMUNOTARGET THERAPY: ASPETTI GENERALI

IMMUNOTARGET THERAPY: ASPETTI GENERALI IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,

More information

Principles of Adaptive Immunity

Principles of Adaptive Immunity Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors

More information

Immunotherapy of HNC: immune mechanisms and therapeutic targets

Immunotherapy of HNC: immune mechanisms and therapeutic targets Immunotherapy of HNC: immune mechanisms and therapeutic targets Ourania Tsitsilonis, MD, PhD Department of Biology National & Kapodistrian University of Athens What does the Immune System see in Cancer?

More information

Immunotherapy & radiotherapy

Immunotherapy & radiotherapy Immunotherapy & radiotherapy Eric Deutsch MD PhD Gustave Roussy Cancer Campus Image courtesy of Gustave Roussy Institute Disclosure & Disclaimer An honorarium is provided by Accuray for this presentation

More information

CANCER IMMUNOTHERAPY IN VETERINARY ONCOLOGY

CANCER IMMUNOTHERAPY IN VETERINARY ONCOLOGY CANCER IMMUNOTHERAPY IN VETERINARY ONCOLOGY Matt Dowling, DVM, MS, Practice limited to Oncology Staff Oncologist VCA Northwest Veterinary Specialists Overview Cancer and the immune system Introduction

More information

NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies

NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,

More information

Natural Killer (NK) cells and Programmed cell death protein-1 (PD-1)

Natural Killer (NK) cells and Programmed cell death protein-1 (PD-1) Natural Killer (NK) cells and Programmed cell death protein-1 (PD-1) Sujan Badal, MS2; Zachary B. Davis, PhD; Jeffrey Miller, MD Department of Medicine, Division of Hematology, Oncology, and Transplantation

More information

Immunotherapy in Lung Cancer - TLR9 as a therapeutic target -

Immunotherapy in Lung Cancer - TLR9 as a therapeutic target - Immunotherapy in Lung Cancer - TLR9 as a therapeutic target - Wilfried Eberhardt,, MD Head of Outpatient Unit, Dept. of Internal Medicine (Cancer Research) West German Cancer Centre Essen University Hospital

More information

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016

Immuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016 Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival

More information

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers

More information